FDA D.I.S.C.O. Burst Edition: FDA approvals of Tukysa (tucatinib) with trastuzumab for colorectal cancer and Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma episode artwork

EPISODE · Feb 16, 2023 · 6 MIN

FDA D.I.S.C.O. Burst Edition: FDA approvals of Tukysa (tucatinib) with trastuzumab for colorectal cancer and Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma

from FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) · host U.S. Food and Drug Administration, Center for Drug Evaluation and Research

Listen to a soundcast of the January 19, 2023, FDA approvals of Tukysa (tucatinib) with trastuzumab for colorectal cancer and Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma.

Episode metadata supplied by the publisher feed · Published Feb 16, 2023

Embed this episode

Ready to play

FDA D.I.S.C.O. Burst Edition: FDA approvals of Tukysa (tucatinib) with trastuzumab for colorectal cancer and Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma

0:00 6:29

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)?

This episode is 6 minutes long.

When was this FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode published?

This episode was published on February 16, 2023.

Can I download this FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!